ArticleBritish journal of cancer2017
Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study.
Article in British journal of cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 3 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- Impact of androgen deprivation therapy and androgen receptor pathway inhibitors on cardiac structure and function evaluated by echocardiography in males with prostate cancer: a systematic review and meta-analysis.International urology and nephrology · 2026Pooled it
- Androgen deprivation therapy use and the risk of heart failure in patients with prostate cancer: a systematic review and meta-analysis.BMC cardiovascular disorders · 2024Pooled it
- Hormonal prostate cancer therapies and cardiovascular disease: a systematic review.Heart failure reviews · 2022Pooled it
- Specialist Referral for Cardiovascular Risk in Patients With Prostate Cancer: A Randomized Clinical Trial.JAMA internal medicine · 2026Article
- Sex and age disparities in goserelin safety: a global pharmacovigilance study.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Racial disparity in microvascular function among non-Hispanic white and non-Hispanic black men with newly diagnosed prostate cancer.Physiological reports · 2026Article
- Cardiovascular Safety Landscape of ADT in Prostate Cancer Treatment Based on Real-World Analysis.Cancer medicine · 2025Article
- Adherence to American Cancer Society Guideline and Mortality in Men With Nonmetastatic Prostate Cancer.JAMA network open · 2025Article
- Burden of Chronic Health Conditions Among People With HIV and Common Non-AIDS-Defining Cancers.Journal of the National Comprehensive Cancer Network : JNCCN · 2025Article
- Major adverse cardiovascular events among Black and White Veterans receiving androgen deprivation therapy for prostate cancer: a retrospective cohort study.Cardio-oncology (London, England) · 2025Article
- The Effect of Androgen Deprivation Therapy on the Cardiovascular System in Advanced Prostate Cancer.Medicina (Kaunas, Lithuania) · 2024Review
- Social Determinants of Health Mediate Racial Disparities in Cardiovascular Disease in Men With Prostate Cancer.JACC. CardioOncology · 2024Article
- Comparison of salvage radical prostatectomy vs. salvage ablation therapy for biopsy-proven radio-recurrent localized prostate cancer.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2024Article
- Metabolic and cardiovascular disease risk for Zimbabwean men with prostate cancer receiving long-term androgen deprivation therapy.Research square · 2023Article
- Determining the association of rurality and cardiovascular disease among prostate cancer survivors.Urologic oncology · 2023Article
- Cardiovascular Complications in Patients with Prostate Cancer: Potential Molecular Connections.International journal of molecular sciences · 2023Review
- Castration of Male Mice Induces Metabolic Remodeling of the Heart.Journal of the Endocrine Society · 2022Article
- Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies : Position paper of the Heart Failure Working Group of the Austrian Society of Cardiology.Wiener klinische Wochenschrift · 2022Article
- Risks of metabolic diseases and androgen deprivation therapy for prostate cancer in a Chinese population: a prospective multi-centre cohort study.International urology and nephrology · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
Abstract
backgroundAs androgen deprivation therapy (ADT) is increasingly being used in men with localised prostate cancer, our goal was to examine the association between ADT and the risk of cardiovascular disease (CVD).
methodsWe conducted a prospective cohort study using records of a large health-care system in California. The study included men with newly diagnosed localised prostate cancer (1998-2008) who initially underwent active surveillance (N=7637) and were followed through 2010. We examined 10 individual CVD outcomes. Cox proportional hazard models incorporated time-varying treatment variables and controlled for race/ethnicity, age, and tumour characteristics, recurrence risk, CVD medication use, and CVD risk factors.
resultsOf the 7637 subjects, nearly 30% were exposed to ADT. In the multivariable analyses, ADT was associated with an increased risk of heart failure (adjusted HR=1.81, 95% CI 1.40-2.32) in men without preexisting CVD. Elevated risks of arrhythmia (adjusted HR=1.44, 95% CI 1.02-2.01), and conduction disorder (adjusted HR=3.11, 95% CI 1.22, 7.91) were only observed among patients with preexisting CVD.
conclusionsIn men with clinically localised prostate cancer who were initially under active surveillance, ADT was associated with a greater risk of heart failure in men without any preexisting CVD. We also found an increased risk of arrhythmia and conduction disorder in men with preexisting CVD. This study provides the basis for identifying high-risk men treated with ADT who might benefit from regular cardiac monitoring and lifestyle modification recommendations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.